Non-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

October 2019 | Volume 18 | Issue 10 | Editorials | 1059 | Copyright © October 2019

Rosemary deShazo MD,a0 Razieh Soltani-Arabshahi MD,b Shalini Krishnasamy MD,ª Richard G. Langley MD FRCPC,c Sunil Kalia MD MHSc FRCPC,d Mona Ståhle MD PhD,E Wayne Langholff PhD,f Kavitha Goyal MD,g Steve Fakharzadeh MD PhD,g Claudia Galindo MD,g Bhaskar Srivastava MD PhD,g Gerald Krueger MDª

ªUniversity of Utah School of Medicine, Department of Dermatology, Salt Lake City, UT

BCleveland Clinic, Cleveland, OH

cDalhousie University, Division of Clinical Dermatology and Cutaneous Science, Halifax, Nova Scotia, Canada 

DUniversity of British Columbia, Department of Dermatology and Skin Science, Vancouver, British Columbia, Canada

EKarolinska Institutet, Department of Medicine, Stockholm, Sweden

fJanssen Research & Development, LLC, Spring House, PA 

gJanssen Scientific Affairs, LLC, Horsham, PA

PSOLAR is sponsored by Janssen Scientific Affairs, LLC, Horsham, PA.

AbbVie, Eli Lilly, Celgene, Janssen-Cilag, Novartis, Pfizer, and Wyeth Pharmaceuticals. Wayne Langholff, Kavitha Goyal, Steve Fakharzadeh, Claudia Galindo, and Bhaskar Srivastava are employees of Janssen Research & Development, LLC or Janssen Scientific Affairs, LLC, and may own company stock. Gerald Krueger received fees as a Consultant or Advisory Board member for Abbott, Amgen, Boehringer Ingleheim, Janssen Biotech, Eli Lilly, Novartis, Pfizer, PSOLAR/Johnson & Johnson, and Sun Pharma; lecture fees from Abbott, Amgen, Janssen Biotech, Novartis, and Eli Lilly; and received partial stipend support for a clinical research fellowship from Abbott and the National Psoriasis Foundation. All other authors do not have any conflicts of interests to declare.

This observational study was registered with NCT00508547. An institutional review board or ethics committee approved the PSOLAR protocol at each site, and the study was conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines on Good Clinical Practices and principles of the Declaration of Helsinki as well as other national and local laws and regulations, as appropriate.
Acknowledgments: The authors wish to thank Cynthia Arnold, BS (Janssen Scientific Affairs, LLC), and Chastity Bradley, PhD (Synchrogenix, A Certara Company), for providing editorial assistance and medical writing support for the manuscript.

  1. Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, et al. The risk of cancer in patients with psoriasis: A population-based cohort study in the health improvement network. JAMA Dermatol. 2016;152:282-290. doi: 10.1001/jamadermatol.2015.4847
  2. Pouplard C, Brenaut E, Horreau C, et al. Risk of cancer in psoriasis: A systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013;27 Suppl 3:36-46. doi: 10.1111/jdv.12165
  3. Shelton E, Laharie D, Scott FI, et al. Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: A systematic review and meta-analysis. Gastroenterology. 2016;151:97-109.e104. doi: 10.1053/j.gastro.2016.03.037
  4. Papp KA, Strober B, Augustin M, et al. PSOLAR: Design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol. 2012;11:1210-1217.


Rosemary deShazo MD